Video

MSI Testing Is Crucial in Colorectal Cancer

Author(s):

Michael J. Overman, M.D.

Genetic testing – particularly for microsatellite instability (MSI) – is an important step for all patients diagnosed with colorectal cancer.

Genetic testing — particularly for microsatellite instability (MSI) – is an important step for all patients diagnosed with colorectal cancer (CRC), says Michael J. Overman, M.D., associate professor, department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center.

Recent findings presented at the 2017 Gastrointestinal Cancers Symposium found that the immunotherapy agent Opdivo (nivolumab) drastically improved response rates and progression-free survival in patients with metastatic CRC who tested positive for MSI. Since the agent is so promising, it is important to identify patients who would benefit from this treatment.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of Crispino
Image of Dr. Reznick
Picture of Joy Anderson
Some patients with relapsed/refractory diffuse large B-cell lymphoma whose disease progressed after CAR-T cell therapy, responded to odronextamab.
Anne M. Reb is a nurse practitioner with City of Hope.
Image of woman with brown hair.
Image of man with black hair.
Image of bald man.
Image of man.
Image of Kumar.
Related Content
Medical test.
April 22nd 2025

Oncodetect Test Aims to Detect Recurrence Risk Across Solid Tumors

Spencer Feldman
The Oncodetect test detects molecular residual disease across solid tumors using circulating tumor DNA to inform recurrence risk and treatment decisions.
Teri Greige with medals
February 16th 2023

The Sport of Cancer: How One Survivor Linked Ironman Training and Colorectal Cancer

Brielle Benyon
Teri Griege completed an Ironman triathlon in 2009, and less than a month later received a stage 4 colorectal cancer diagnosis. In this episode of Cancer Horizons, she shared her story.
Image of Clinical trial text.
April 12th 2025

First Patient Dosed With KSQ-004EX In Solid Tumor Clinical Trial

Alex Biese
KSQ-004EX is being evaluated in solid tumors including melanoma, non-small cell lung, head and neck, colorectal, pancreatic and cervical cancer.
‘Let’s Go After This Thing and Fight’ Urges a Long-Time Survivor of Early-Onset CRC
January 27th 2022

‘Let’s Go After This Thing and Fight’ Urges a Long-Time Survivor of Early-Onset CRC

Jamie Cesanek
In this episode of the “Cancer Horizons” podcast, a woman living with colorectal cancer who was diagnosed 14 years ago at age 29 discusses what it was like to be the youngest person in the treatment room, and how she found another community of young survivors.
CURE spoke with Dr. Michael K. Wong and Dr. Diwakar Davar about the use of ctDNA for patients with melanoma, and where the field may be headed.
April 11th 2025

What Role May ctDNA Have in Melanoma Management?

Dr. Michael K. Wong
CURE spoke with Dr. Michael K. Wong and Dr. Diwakar Davar about the use of ctDNA for patients with melanoma, and where the field may be headed.
Graphic with the words "FDA APPROVED" resembling a stamp of approval
April 8th 2025

FDA Approves Opdivo Plus Yervoy For Some With Colorectal Cancer

Alex Biese
The FDA has approved Opdivo with Yervoy for patients 12 years old and older with MSI-H or dMMR colorectal cancer.